Prognostic significance of splicing factor gene mutations and the impact of Venetoclax in AML treatment

A retrospective study analyzes the impact of splicing factor gene mutations and Venetoclax treatment regimen on adult patients with AML, revealing shorter survival rates with intensive therapy but improved outcomes with low-intensity therapy and Venetoclax. The chapter highlights the importance of developing new prognostic models considering these factors.